PCSK9 and atherosclerosis: In summary, the lack of association between LDL-cholesterol and risk of ASCVD may be interpreted as a testimony to the prevalent and intensive treatment of elevated LDL-cholesterol in individuals with diabetes in Denmark, and not as a contradiction to evidence from clinical trials showing that lowering LDL-cholesterol from already low levels with ezetimibe [29] and proprotein convertase subtilisin/kexin type 9 inhibitors [30, 31] reduces risk of ASCVD in individuals with diabetes.